Neil Floch MD FACS FASMBS DABOM
banner
neilflochmd.bsky.social
Neil Floch MD FACS FASMBS DABOM
@neilflochmd.bsky.social
1.9K followers 2.8K following 160 posts
Bariatric and Foregut Surgeon passionate about educating and advocating about obesity causes and treatments including medications and bariatric surgery - Associate Professor of Surgery Yale School of Medicine and a self-taught artist - Tufts Graduate
Posts Media Videos Starter Packs
Intussusception is a condition or complication where one part of the intestine telescopes into another. It can occur from a mass of the bowel such as a polyp or growth or from fixed point such as in bowel or gastric bypass surgery. #obesity #pediatric surgery #gastricbypass
The Yale Obesity Symposium
A one-day 7 CME event
November 21 2025
NEW developments in
Obesity Treatment

Speakers including:

Lee Kaplan MD PhD
Ania Jastreboff MD PhD
John Morton MD

Register NOW! cme.edu
@Yale @YaleMed @YaleSurgery
Obesity GLP-1ra Semaglutide Tirzepatide Retatrutide GLP1
Reposted by Neil Floch MD FACS FASMBS DABOM
From our September issue: Bile acids in the crosshairs for hypoglycaemia after gastric bypass, a News & Views from Marzieh Salehi (£) bit.ly/3H6tHhG #EndoSky #MedSky
The Impact of Bariatric Surgery on Cardiovascular Risk Factors and Outcomes: A Systematic Review | Cureus
x.com/neilflochmd/...
x.com
Reposted by Neil Floch MD FACS FASMBS DABOM
Oral semaglutide cost-effective vs. liraglutide—even at 50% ⤵️ price

🔹 🇬🇧 modelled data: ⤴️ QALYs (+0.18) & ⤵️ comp.

🔸 💊 = ⤵️ Rx burden vs. daily 💉

🔹 Results robust across sensitivity analyses

⚠️ funded by NovoNordisk

👉 Challenges low-cost liraglutide, supports 🎯 oral GLP-1 use

🔗 ggdocs.co/9h0bz1
Reposted by Neil Floch MD FACS FASMBS DABOM
📢 #GLP1 ⤵️ kidney decline, CV events & mortality in CKD❗️

🔹 Meta-analysis of 18K pts w/ eGFR <60:
⤵️ eGFR decline ≥50% (OR 0.72)
⤵️ 💔 (OR 0.86)
⤵️ ☠️ (OR 0.77)

🔸 ⤵️⤵️ with human GLP-1 backbone

🥇Evidence across CKD stages—not just macroalbuminuria

👉 GLP-1 now a key 🎯 in CKD + #T2D

🔗 ggdocs.co/tnqomz
Reposted by Neil Floch MD FACS FASMBS DABOM
📢 Danuglipron dropped—can orforglipron still be the “oral GLP-1 that delivers”?

🔹 Pfizer halts danuglipron after liver signal

🔸 Orforglipron P2=HbA1c ⤵️2.1%, Wt ⤵️14.7%, no liver signal

🔹 P3 2025—will it safely deliver?

👉 Small molecule GLP-1: blockbuster or cautionary tale?

🔗 ggdocs.co/5qu8y3
ggdocs.co
A message from @OMAsocial past PRESIDENT and #OAC board member @DrAngelaFitch:

IT IS TIME for #GLP1 #obesity medication pharmaceutical producers to:

#betheHERO #betheHERO!

Cut the cost to $299 a month and Increase access to care!